While the consequences of surface markers such as TF and soluble factors such as CCL2 are strongly linked to SNAEs including neurological and cardiovascular disease in ART-treated individuals, future studies will be needed to identify both the mechanisms responsible for, and functional consequences of, dysregulated monocyte gene expression, as well as the potential impact of therapeutic targeting these pathways. The gene discussed is CCL2; the disease is cardiovascular disorder.